Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression

Table 1 Characteristics of the studies included in the analysis

Study	Publication year	Population	Follow-up (months)	Design	Dual lipid-lowering therapy				Statin monotherapy
Study	Publication year	Population	Follow-up (months)	Design	N	*Treatment*	*Baseline LDL-C*	*Baseline non-HDL-C*	N	*Treatment*	*Baseline LDL-C*	*Baseline non-HDL-C*
HEAVEN [14]	2012	SAP	12	Single-blinded. RCT	42	Atorvastatin 80 mg/day + Ezetimibe 10 mg/day	119.9	143.1	47	Standard statin therapy	104.4	131.5
OCTIVUS [15]	2016	ACS	11.6	Double-blinded. RCT	39	Atorvastatin 80 mg/day + Ezetimibe 10 mg/day	142.9	162.1	41	Atorvastatin 80 mg/day + Placebo	158.3	177.6
ZEUS [16]	2014	ACS	6	Open label. Non RCT	50	Atorvastatin 20 mg/day + Ezetimibe 10 mg/day	116.2	137.5	45	Atorvastatin 20 mg/day	114.3	137.8
Hibi et al. [17]	2018	ACS	10	Open label. RCT	50	Pitavastatin 2 mg/day + Ezetimibe 10 mg/day	123.0	146.0	53	Pitavastatin 2 mg/day	126.0	150.0
PRECISE [18]	2015	ACS/SAP Basal LDL-C > 100 mg/dl	10.1	Single-blinded. RCT	100	Atorvastatin^a + Ezetimibe 10 mg/day	109.8	136.2	102	Atorvastatin^a	108.3	132.7
Masuda et al. [19]	2015	SAP Basal LDL-C > 100 mg/dl	6	Open label. RCT	21	Rosuvastatin 5 mg/day + Ezetimibe 10 mg/day	131.8	151.4	19	Rosuvastatin 5 mg/day	123.0	146.2
GLAGOV [20]	2016	SAP	19	Double-blinded. RCT	484	Statin + Evolucumab 420 mg M	92.6	119.4	484	Statin + Placebo	92.4	120.8
ODYSSEY-J [21]	2019	ACS. Basal LDL-C > 100 mg/dl	9	Open label. RCT	93	Statin^b + Alirocumab 75/150 mg Q2W	97.9	124.1	89	Statin^b	95.7	124.4

ACS acute coronary syndrome, M one monthly, Q2W every 2 weeks, RCT randomized clinical trial, SAP stable angina pectoris
^aAtorvastatin was increased by titration with the usual dose range with a treatment goal of LDL-C < 70 mg/dl
^bStandard-of-care

ISSN: 1476-511X